Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTER trial of abelacimab versus apixaban in cancer-associated venous thromboembolism
jRCT2041230073Phase 3Active, not recruiting
- Sponsor
- Anthos Therapeutics
- Start
- Jan 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in venous thromboembolism (VTE) and cancer-associated thrombosis (CAT) comparing Abelacimab with Apixaban (2 arms). Started Jan 2024; status: active, not recruiting.
02
Drugs
abelacimabapixaban
03
Conditions
venous thromboembolism (VTE)cancer-associated thrombosis (CAT)
Beyond the preview
Go deeper on jRCT2041230073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230073.